• Home
  • Browse
    • Current Issue
    • By Issue
    • By Author
    • By Subject
    • Author Index
    • Keyword Index
  • Journal Info
    • About Journal
    • Aims and Scope
    • Editorial Board
    • Editorial Staff
    • Publication Ethics
    • Indexing and Abstracting
    • Related Links
    • FAQ
    • Peer Review Process
    • News
  • Guide for Authors
  • Submit Manuscript
  • Reviewers
  • Contact Us
 
  • Login
  • Register
Home Articles List Article Information
  • Save Records
  • |
  • Printable Version
  • |
  • Recommend
  • |
  • How to cite Export to
    RIS EndNote BibTeX APA MLA Harvard Vancouver
  • |
  • Share Share
    CiteULike Mendeley Facebook Google LinkedIn Twitter Telegram
Iranian Journal of Pharmaceutical Research
Articles in Press
Current Issue
Journal Archive
Volume Volume 17 (2018)
Volume Volume 16 (2017)
Volume Volume 15 (2016)
Volume Volume 14 (2015)
Volume Volume 13 (2014)
Issue Issue 4
Issue Issue 3
Issue Issue 2
Issue Supplement
Issue Issue 1
Volume Volume 12 (2013)
Volume Volume 11 (2012)
Volume Volume 10 (2011)
Volume Volume 9 (2010)
Volume Volume 8 (2009)
Volume Volume 7 (2008)
Volume Volume 6 (2007)
Volume Volume 5 (2006)
Volume Volume 4 (2005)
Volume Volume 3 (2004)
Volume Volume 2 (2003)
Volume Volume 1 (2002)
ebadi, A., razzaghi asl, N., Shahabipour, S., miri, R. (2014). Ab-Initio and Conformational Analysis of a Potent VEGFR-2 Inhibitor: A Case Study on Motesanib. Iranian Journal of Pharmaceutical Research, 13(2), 405-415.
ahmad ebadi; Nima razzaghi asl; Sara Shahabipour; ramin miri. "Ab-Initio and Conformational Analysis of a Potent VEGFR-2 Inhibitor: A Case Study on Motesanib". Iranian Journal of Pharmaceutical Research, 13, 2, 2014, 405-415.
ebadi, A., razzaghi asl, N., Shahabipour, S., miri, R. (2014). 'Ab-Initio and Conformational Analysis of a Potent VEGFR-2 Inhibitor: A Case Study on Motesanib', Iranian Journal of Pharmaceutical Research, 13(2), pp. 405-415.
ebadi, A., razzaghi asl, N., Shahabipour, S., miri, R. Ab-Initio and Conformational Analysis of a Potent VEGFR-2 Inhibitor: A Case Study on Motesanib. Iranian Journal of Pharmaceutical Research, 2014; 13(2): 405-415.

Ab-Initio and Conformational Analysis of a Potent VEGFR-2 Inhibitor: A Case Study on Motesanib

Article 7, Volume 13, Issue 2, Spring 2014, Page 405-415  XML PDF (1348 K)
Document Type: Research article
Authors
ahmad ebadi1; Nima razzaghi asl2; Sara Shahabipour3; ramin miri 4
1Medicinal and Natural Products Chemistry Research Center, Shiraz University of Medical Sciences, Shiraz, Iran. Department of Medicinal Chemistry, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran
2Department of Medicinal Chemistry, School of Pharmacy, Ardabil University of Medical Sciences.
3Medicinal and Natural Products Chemistry Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
4Medicinal and Natural Products Chemistry Research Center, Shiraz University of Medical Department of Medicinal Chemistry, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran 2) Medicinal & Natural Products Chemistry Research Center, Shiraz University of Medical Sciences,
Abstract
Vascular endothelial growth factor receptor-2 (VEGFR-2); a cell surface receptor for vascular endothelial growth factors, is a key pharmacological target involved in the cell proliferation/angiogenesis. It has been revealed that VEGFR-2 induces proliferation through activation of the extracellular signal-regulated kinases pathway. In this regard, targeting the VEGFR-2 has been considered as an efficient route to develop anti-tumor agents. Motesanib is a small-molecule antagonist of VEGFR-1, 2, and 3 (IC50s; 2 nM, 3 nM, 6 nM, respectively). It is an experimental drug candidate undergoing clinical trials against some types of cancer. In the present study, Motesanib (AMG 706) was evaluated in terms of its binding energies with individual amino acids of VEGFR-2 active site (amino acid decomposition analysis). For this purpose, functional B3LYP associated with split valence basis set using polarization functions (Def2-SVP) was used. Comparative conformational analysis of the ligand in optimized and crystallographic states revealed that Motesanib does not necessarily bind to the VEGFR-2 active site in its minimum energy conformer.
Keywords
VEGFR-2; Motesanib; Cancer; B3LYP; DFT
Main Subjects
Medicinal chemistry
Statistics
Article View: 3,831
PDF Download: 6,400
Home | Glossary | News | Aims and Scope | Sitemap
Top Top

Statistics

Journal Management System. Designed by sinaweb.